Tony Berberabe, MPH, is the assistant managing editor for Targeted Therapies in Oncology. Berberabe received his Bachelor of Arts in Biology from Rutgers University and his Master of Public Health from the University of Medicine and Dentistry in New Jersey. He covers genitourinary cancers and myeloproliferative neoplasms. Contact him at aberberabe@targetedonc.com.
Targeted agents, such as Bruton tyrosine kinase inhibitors, PI3K inhibitors, B-cell lymphoma 2 inhibitors, and venetoclax, have delivered improvements in quality of life, progression-free survival, and overall survival for relapsed/refractory chronic lymphocytic leukemia.
Health-related quality-of-life outcomes were maintained among patients with low grade non-muscle invasive bladder cancer who were treated with UGN-102, a chemoablative reverse thermal gel as a primary approach in the single-arm phase 2b Optima II trial.
Interim results from a biomarker-informed preoperative study of infigratinib demonstrated substantial activity and tolerability in patients with localized upper tract urothelial carcinoma, according to findings of a phase 1b trial.
Continued benefit of axicabtagene ciloleucel in patients with relapse/refractory indolent non-Hodgkin lymphoma was observed in the phase 2 ZUMA-5 clinical trial.
RP-3500 dosed at 160-mg dose on a 3 days on/4 days off continuous cycle appears to be the most tolerable for patients with selected ATR-inhibitor-sensitizing DNA damage response alterations, according to the TRESR study.
Response were observed with the combination of sotigalimab and pembrolizumab in patients with metastatic melanoma treated in a phase 1/2 study.
Pertuzumab combined with trastuzumab, and docetaxel revealed comparable survival outcomes with previous studies of patients with metastatic breast cancer, including the CLEOPATRA trial.
Pan-immune-inflammation value made be predictive of survival benefit in patients with ALK-positive non–small cell lung cancer.
A significant proportion of patients who complete 2 years of immune checkpoint inhibitor treatment experience long-term progression-free survival.
Thromboembolic events and risk of progression continue to affect patients with polycythemia vera, but 2 recent advances may affect the natural course of the disease.
Using next-generation sequencing to help inform treatment options is growing in frequency, but the results can be difficult to interpret and implement in clinical practice.
Time to event end points and response rates were similar regardless of which first-line immunotherapy was administered, according to an analysis conducted by the International Metastatic Renal Cell Carcinoma Database Consortium
Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.
For localized colorectal cancer, the use of circulating tumor tDNA for both quantitative and qualitative detection can inform the risk of recurrence and metastatic dissemination.
Neoadjuvant treatment with pembrolizumab, paclitaxel, and cisplatin achieved encouraging tumor responses in patients with locally advanced resectable esophageal squamous cell carcinoma.
Debu Tripathy, MD, said the 39th Annual Miami Breast Cancer Conference is always a well-rounded meeting.
Investigation of intravesical checkpoint-targeted therapy may warrant further investigation in patients with BCG-unresponsive bladder cancer.
Current findings validate and support the clinical utility of enzalutamide regardless of metastatic burden or type of oligometastatic disease, according to the investigators.
Innovative approaches in multiple myeloma that focus on cellular therapies offer hope to patients with multiple myeloma.
The most effective treatment strategy—adjuvant, neoadjuvant, or some combination of adjuvant plus neoadjuvant regimens— remains unclear. Ongoing trials are dedicated to defining the best sequence of treatment.
The improvement in detection and treatment associated with PSMA cannot be overstated, with many investigators describing the advancement as a global practice changer.
In using the biomarker approach to the treatment of triple-negative breast cancer, the challenge for the clinician is prioritizing the available treatment options based on the National Comprehensive Cancer Network guidelines for breast cancer, which focus on active agents, preferred single-agent chemotherapy approaches, and doublet options for certain patients at high risk.
RP-3500 was shown to have a promising safety profile and efficacy in a first-in-human biomarker-driven phase 1/2 study.
Results from the phase 1b CodeBreak 101 study were favorable for the combination of sotorasib and trametinib in patients with colorectal cancer and non–small cell lung cancer.
Investigators reported meaningful pharmacodynamic and pharmacokinetic observations of BT5528 treatment, suggesting tumor penetration in a standard 3+ 3 dose-escalation trial.
Javier L. Munoz, MD, MBA, discussed best options and timing for treating chronic lymphocytic leukemia now and beyond the pandemic
Patients with higher Oncotype DX scores are more likely to complete the recommended 5 years of endocrine therapy.
During an interview,Raymond U. Osarogiagbon, MD, discussed long-term care and outcome disparities of lung cancer in the United States.
Single-agent belantamab demonstrated anti-myeloma activity and a manageable safety profile in the DREAMM-2 phase 2 study.
The emergence of early-phase immune-oncology agents and their respective novel mechanisms of action in head and neck squamous cell carcinoma suggests a new standard of care in the metastatic first-line setting within the next 2 years.